About Osiris Therapeutics (OTCMKTS:OSIR)
Osiris Therapeutics, Inc. researches, develops, manufactures, markets, and distributes regenerative medicine products in the United States. Its products include Grafix and Stravix for treating chronic wounds of diabetic foot ulcers, venous leg ulcers, pressure ulcers, arterial ulcers, and severe burns, as well as surgical and trauma wounds; BIO4 for bone repair and regeneration in spine, trauma, extremity, cranial, and foot and ankle surgeries; and Cartiform for treating articular cartilage lesions in the knee and other joints. The company also develops and markets Menvivo for the repair of meniscus; and TruSkin for treating chronic wounds. It markets and distributes its products directly to physicians, hospitals, and other healthcare providers, as well as through agents and distributors. Osiris Therapeutics, Inc. was founded in 1992 and is headquartered in Columbia, Maryland.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Annual Sales$118.51 million
Price / Sales2.19
Price / CashN/A
Book Value$1.20 per share
Price / Book6.25
EPS (Most Recent Fiscal Year)N/A
Return on EquityN/A
Return on AssetsN/A
Osiris Therapeutics (OTCMKTS:OSIR) Frequently Asked Questions
What is Osiris Therapeutics' stock symbol?
Osiris Therapeutics trades on the OTCMKTS under the ticker symbol "OSIR."
Who are some of Osiris Therapeutics' key competitors?
Some companies that are related to Osiris Therapeutics include Bavarian Nordic (BVNRY), La Jolla Pharmaceutical (LJPC), Coherus BioSciences (CHRS), Novavax (NVAX), Jounce Therapeutics (JNCE), Heska (HSKA), Voyager Therapeutics (VYGR), Fate Therapeutics (FATE), EntreMed (CASI), Mesoblast (MESO), BioCryst Pharmaceuticals (BCRX), PDL Biopharma (PDLI), Solid Biosciences (SLDB), Vericel (VCEL) and Nightstar Therapeutics (NITE).
Who are Osiris Therapeutics' key executives?
Osiris Therapeutics' management team includes the folowing people:
- Mr. Philip R. Jacoby Jr., Interim Principal Accounting Officer (Age 65)
- Mr. Jason Keefer, Interim CEO & Pres (Age 46)
- Ms. Linda L. Chang, Chief Financial Officer (Age 52)
- Dr. Alla N. Danilkovitch Ph.D., Chief Scientific Officer (Age 54)
- Mr. Richard Skow, Gen. Counsel & Corp. Sec.
Has Osiris Therapeutics been receiving favorable news coverage?
Media headlines about OSIR stock have trended somewhat positive on Tuesday, Accern Sentiment reports. Accern rates the sentiment of news coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Osiris Therapeutics earned a media sentiment score of 0.11 on Accern's scale. They also gave news headlines about the biotechnology company an impact score of 47.96 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.
How do I buy shares of Osiris Therapeutics?
Shares of OSIR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Osiris Therapeutics' stock price today?
One share of OSIR stock can currently be purchased for approximately $7.50.
How big of a company is Osiris Therapeutics?
Osiris Therapeutics has a market capitalization of $268.61 million and generates $118.51 million in revenue each year. Osiris Therapeutics employs 350 workers across the globe.
How can I contact Osiris Therapeutics?
Osiris Therapeutics' mailing address is 7015 ALBERT EINSTEIN DRIVE, COLUMBIA MD, 21046. The biotechnology company can be reached via phone at 443-545-1800 or via email at [email protected]
MarketBeat Community Rating for Osiris Therapeutics (OSIR)MarketBeat's community ratings are surveys of what our community members think about Osiris Therapeutics and other stocks. Vote "Outperform" if you believe OSIR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OSIR will underperform the S&P 500 over the long term. You may vote once every thirty days.
Osiris Therapeutics (OTCMKTS:OSIR) Analyst Ratings History
(Data available from 4/24/2016 forward)
Osiris Therapeutics (OTCMKTS:OSIR) Earnings History and Estimates Chart
Osiris Therapeutics (OTCMKTS OSIR) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|11/6/2015||Q315||$0.06||($0.02)||$25.40 million||$24.30 million||View||N/A|
|8/5/2015||Q215||$0.06||$0.03||$23.60 million||$23.70 million||View||N/A|
|5/8/2015||Q115||$0.04||$18.40 million||$21.00 million||View||N/A|
|3/5/2015||Q414||$0.05||$0.03||$18.53 million||$19.50 million||View||N/A|
|11/7/2014||Q314||($0.01)||$0.02||$14.80 million||$17.20 million||View||N/A|
|8/7/2014||Q214||$0.16||($0.04)||$11.00 million||$13.30 million||View||N/A|
|5/12/2014||($0.08)||($0.02)||$9.00 million||$10.05 million||View||N/A|
|3/5/2014||Q413||$0.65||$0.11||$7.50 million||$8.10 million||View||N/A|
|11/1/2013||Q313||($0.10)||($0.05)||$6.70 million||$6.88 million||View||N/A|
|8/5/2013||Q2 2013||($0.09)||($0.11)||$4.35 million||$5.29 million||View||N/A|
|5/7/2013||Q1 2013||($0.09)||($0.08)||$3.53 million||$4.06 million||View||N/A|
|11/5/2012||Q312||($0.14)||($0.09)||$1.89 million||$2.15 million||View||N/A|
Osiris Therapeutics (OTCMKTS:OSIR) Dividend History by Quarter
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
Osiris Therapeutics (OTCMKTS OSIR) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 44.60%
Institutional Ownership Percentage: 0.28%
Osiris Therapeutics (OTCMKTS OSIR) Insider Trading History
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|5/27/2014||Matthew Paul Neumayer||Insider||Sell||3,750||$16.10||$60,375.00|| |
|5/21/2014||Philip Jacoby, Jr.||CFO||Sell||15,947||$15.43||$246,062.21||12,500|| |
|3/14/2014||Michelle Leroux Williams||Insider||Sell||61,934||$14.09||$872,650.06|| |
|11/25/2013||Philip Jacoby, Jr.||CFO||Sell||18,372||$15.99||$293,768.28||12,500|| |
|11/15/2013||Michelle Leroux Williams||Insider||Sell||24,500||$15.50||$379,750.00|| |
|8/20/2013||Matthew Paul Neumayer||Insider||Sell||11,375||$19.75||$224,656.25|| |
Osiris Therapeutics (OTCMKTS OSIR) News Headlines
Osiris Therapeutics (OTCMKTS:OSIR) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Osiris Therapeutics (OTCMKTS:OSIR) Income Statement, Balance Sheet and Cash Flow Statement
Osiris Therapeutics (OTCMKTS OSIR) Stock Chart for Tuesday, April, 24, 2018